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Abstract
Background: Aortic stiffness is increasingly used as an independent predictor of adverse cardiovascular outcomes.
We sought to compare the impact of transcatheter aortic valve implantation (TAVI) and surgical aortic valve
replacement (SAVR) upon aortic vascular function using cardiovascular magnetic resonance (CMR) measurements of
aortic distensibility and pulse wave velocity (PWV).
Methods and results: A 1.5 T CMR scan was performed pre-operatively and at 6 m post-intervention in 72 patients
(32 TAVI, 40 SAVR; age 76 ± 8 years) with high-risk symptomatic severe aortic stenosis. Distensibility of the
ascending and descending thoracic aorta and aortic pulse wave velocity were determined at both time points.
TAVI and SAVR patients were comparable for gender, blood pressure and left ventricular ejection fraction. The TAVI
group were older (81 ± 6.3 vs. 72.8 ± 7.0 years, p < 0.05) with a higher EuroSCORE II (5.7 ± 5.6 vs. 1.5 ± 1.0 %, p < 0.
05). At 6 m, SAVR was associated with a significant decrease in distensibility of the ascending aorta (1.95 ± 1.15 vs. 1.
57 ± 0.68 × 10−3mmHg−1, p = 0.044) and of the descending thoracic aorta (3.05 ± 1.12 vs. 2.66 ± 1.00 × 10−3mmHg−1,
p = 0.018), with a significant increase in PWV (6.38 ± 4.47 vs. 11.01 ± 5.75 ms−1, p = 0.001). Following TAVI, there was
no change in distensibility of the ascending aorta (1.96 ± 1.51 vs. 1.72 ± 0.78 × 10−3mmHg−1, p = 0.380), descending
thoracic aorta (2.69 ± 1.79 vs. 2.21 ± 0.79 × 10−3mmHg−1, p = 0.181) nor in PWV (8.69 ± 6.76 vs. 10.23 ± 7.88 ms−1,
p = 0.301) at 6 m.
Conclusions: Treatment of symptomatic severe aortic stenosis by SAVR but not TAVI was associated with an
increase in aortic stiffness at 6 months. Future work should focus on the prognostic implication of these findings to
determine whether improved patient selection and outcomes can be achieved.
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Background
Aortic valve stenosis is the most common valve disease in
the western world [1] with a burden that is excepted to
double within the next 50 years. With over 50 years of ex-
perience, surgical aortic valve replacement (SAVR) is con-
sidered the gold standard therapy for symptomatic severe
aortic stenosis. However, many patients are considered
too high risk for conventional surgery and transcatheter
aortic valve implantation (TAVI) is now an established
treatment option for those deemed inoperable [2].
Degenerative aortic stenosis can be viewed as part of a
continuum that comprises not only valvular dysfunction
but also a reduction in aortic compliance [3] which
independently contributes to increased afterload [4] and de-
creased left ventricular function. Increased aortic stiffening
is detrimental to arterio-ventricular coupling and coronary
perfusion and is an independent predictor of future cardio-
vascular events and mortality in the general population,
essential hypertension, diabetes mellitus, end stage renal
failure and in the elderly [5]. Measurement of aortic
stiffness is therefore increasingly used in clinical practise as
a prognostic indicator.
Cardiovascular magnetic resonance (CMR) offers a ro-
bust, reproducible, non-invasive method of assessing both
local and regional properties of the aortic wall [6]. Two
standard indices of aortic stiffness can be expressed; aortic
distensibility and pulse wave velocity, and there is a strong
inverse linear relationship reported between these two
measurements [7, 8].
The elastic property of the aorta is in part dependent
upon the perfusion of the aortic wall via vasa vasorum
flow. We hypothesised, based upon the difference in tech-
niques, that more favourable measures of aortic stiffness
would be observed following TAVI rather than SAVR.
Ultimately, this may herald prognostic implications and
guide future patient selection.
The primary aim of this study was to use CMR to seri-
ally compare the effects of TAVI and SAVR on aortic
stiffness, before and 6 m after treatment for severe
symptomatic aortic stenosis.
Methods
Study population
A total of 127 patients were prospectively recruited with
severe trileaflet degenerative AS after being referred for
either TAVI (n = 77) or SAVR (n = 50) at the University
Hospitals of Leeds and Leicester, UK, between July 2008
and December 2013. Severe AS was classified by transtho-
racic echocardiography (TTE) as an aortic valve area of
≤1.0 cm2. Decision for TAVI was taken by a multidiscip-
linary heart team in accordance with international guid-
ance. Older, higher-risk (higher EuroSCORE) SAVR
patients were preferentially recruited wherever possible to
facilitate comparable baseline demographics. Exclusion
criteria included any contraindication to CMR as well as
patients with a known bicuspid aortic valve or aortopathy.
The study was approved by the national ethics committee
(NRES Committee Yorkshire & the Humber—Leeds West,
UK), complied with the Declaration of Helsinki and all
patients provided written informed consent.
Transcatheter aortic valve implantation
TAVI was performed under general anaesthesia by high-
volume operators with >5 years’ experience. Either an 18 F
CoreValve Revalving system (CVR, Medtronic, Minneap-
olis, Minnesota, USA) or an 18 F or 20 F Lotus™ Aortic
Valve system (Boston Scientific Corporation, Natick, USA)
were deployed as previously described [9, 10].
Surgical aortic valve replacement
SAVR was performed by standard midline sternotomy with
cardiopulmonary bypass and mild hypothermia. Biological
or mechanical prostheses of varying sizes were used accord-
ing to surgical preference; concomitant coronary artery
bypass grafting was performed as indicated. No patient
underwent aortic root or ascending aortic reconstruction.
CMR protocol
For each individual patient, identical baseline pre-operative
and 6-month post-operative scans were performed on the
same 1.5 T MR system (Phillips Intera, Best, The
Netherlands or Siemens Avanto Erlangen, Germany).
Multi-slice, multi-phase cine imaging was performed
using a standard steady-state free precession (SSFP) pulse
sequence in the vertical long-axis, four-chamber, left
ventricular outflow tract (LVOT) views, and in the short
axis (breath-held, 10 mm thickness, 0 mm gap, acquired
temporal resolution 30 phases, typical field of view (FOV)
340 mm, acquired spatial resolution 1.88 × 1.88 × 10 mm,
TR 3.1 ms, TE 1.55 ms) to cover the entire left and right
ventricles. Through-plane velocity encoded (VENC) phase
contrast imaging was performed perpendicular to the
aortic valve jet at the aortic sinotubular junction (VENC
250–500 cm/s, retrospective gating, slice thickness 6 mm,
acquired temporal resolution 40 phases, typical FOV
340 mm, acquired spatial resolution 1.56 × 2.23 × 6 mm,
TR 5 ms, TE 3 ms, breath-held, which for a heart rate of
60 beats per minute was equivalent to 13 s).
For aortic distensibility, brachial artery blood pressure
was recorded by Dinamap (Critikon, Tampa, USA) immedi-
ately prior to high temporal resolution multi-phase SSFP
cine imaging (retrospective gating, slice thickness 8 mm,
acquired spatial resolution 1.07 × 1.8 × 8 mm, acquired
temporal resolution 50 phases, TR 3 ms, TE 1.5 ms, breath-
held, which for a heart rate of 60 beats per minute was
equivalent to 12 s) acquired transverse to the ascending
and descending thoracic aorta at the level of the pulmonary
artery bifurcation. Aortic pulse wave velocity was assessed
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using identical geometric planning with retrospectively
gated, through-plane, phase-contrast velocity encoded
images (single slice, 8 mm thick, acquired spatial resolution
2.5 × 2.67 × 8 mm, TR 4.6 ms, TE 2.7 ms, acquired tem-
poral resolution 50 phases, typical FOV 350, and VENC
200–500 cm/s, breath-held, which for a heart rate of 60
beats per minute was equivalent to 13 s).
CMR image analysis
Image analysis was performed in line with international
guidance [11], blinded to patient details, using off-line com-
mercially available software (QMass V7.5 and QFlow V7.2,
Medis, Leiden, The Netherlands). Standard criteria were
employed to delineate LV endocardial and epicardial borders
at end-diastole and end-systole for LV mass and volumes.
Papillary muscles were excluded from the LV cavity and in-
cluded within the LV mass for the purpose of analysis. Aor-
tic valve flow indices were quantified using cross-sectional
phase contrast images with contouring of the aortic lumen
to derive peak forward flow velocity (m/s), and forward and
backward flow volumes (ml), for the calculation of trans-
valvular pressure gradient and regurgitant fraction (%).
To derive the aortic distensibility of the ascending and
descending thoracic aorta, cross sectional measurements
were made by manual planimetry of the endovascular-
blood pool interface for each phase to determine the
maximal and minimal aortic dimensions (Fig. 1a). Aortic
distensibility (mmHg−1) was calculated using the equation:
Distensibility
¼ Aortic max lumen area − Aortic min lumen areað Þ
= Aortic min lumen area x Systolic BP – Diastolic BP½ ð Þ
Aortic PWV (m/s) was calculated by dividing the distance
separating two locations and the transit time needed to
cover this distance [12]. Analysis was performed using a
validated software (PMI v0.4, https://github.com/plaresm
edima/PMI-0.4-Runtime-CMRLeeds) based on IDL 6.4
(ITT Visual Information Systems, Boulder, USA) [13]. The
distance between the ascending and descending aorta was
measured manually from the sagittal/oblique cines of the
aortic arch (Fig. 1b). Transit time was calculated using the
foot-foot delay method from velocity encoded images of
the ascending and descending aorta, manually contoured to
derive velocity-time curves (Fig. 1c) [14].
Statistical analysis
Continuous variables are presented as mean ± SD. Normal-
ity was determined by the Shapiro-Wilk test. Frequencies
are reported as number (%). The Student t test and
Wilcoxon signed rank test were used for continuous vari-
ables, and χ2 or Fisher’s exact test for categorical compari-
sons. Changes over time were assessed for differences
between the treatment groups and clinical variables by two-
way repeated measures analysis of variance (ANOVA). Pre-
dictors of functional change were evaluated by a stepwise
linear regression model with baseline measurements en-
tered as covariate factors. All statistical analyses were per-
formed using PASW software (V.21.0 SPSS, IBM, Chicago,
USA); two-sided p < 0.05 considered statistically significant.
Results
Seventy-two patients (32 TAVI, 40 SAVR) with paired
pre-operative and 6 m post-operative CMR scans were in-
cluded for analysis. Reasons for non-completion of the
CMR protocol were varied and are depicted in Fig. 2. Base-
line characteristics of the study population are shown in
Table 1. For both individual groups, key demographic and
haemodynamic parameters of the excluded patients were
not statistically different to those included for analysis
Fig. 1 a Ascending aortic cross-sectional measurements made by manual planimetry of the aortic endovascular-blood pool interface at minimal
and maximal distension. b Sagittal oblique CMR image from which the length of the aortic arch is manually measured. The image is subsequently
used to determine site of acquisition of phase contrast cines. c Time-Velocity curve derived using PMI software to calculate foot-foot delay
(curves are automatically adjusted/overlaid to accommodate time delay)
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(Table 2), indicating that our study patients were represen-
tative of the larger population. The TAVI group were older
with a higher predicted 30day mortality risk. The aortic di-
mensions between the SAVR and TAVI groups were both
equivalent and within published normal reference ranges
[15] in keeping with our exclusion criteria (Table 1).
Procedural data
For the TAVI group, 25(78 %) patients received a Medtro-
nic CoreValve and 7(22 %) a Boston Scientific Lotus valve.
The femoral access route was used for 30(94 %) and the
subclavian artery for the remaining 2(6 %) patients. Proced-
ural success was 100 % with an average catheterisation time
of 159 ± 48 min, fluoroscopy time of 25 ± 7 min and 146 ±
48 ml of contrast administered.
In the surgical group, five patients received a mechan-
ical prosthesis (either Sorin Carbomedics or St Jude’s
mechanical) and the remaining 35(88 %) a tissue bio-
prosthesis (Sorin mitroflow, Edwards Perimount Magna,
Medtronic Hancock, Hancock II and Mosaic, Vascutek
Terumo Aspire). Eleven (28 %) received concomitant
coronary bypass grafting, of which 6 involved use of the
left internal mammary artery. For the group as a whole,
the average bypass time was 108 ± 50 min and average
cross clamp time 81 ± 43 min. The average length of stay
in intensive care was 3.5 ± 2.8 days.
Aortic valve haemodynamics and LV reverse remodelling
Results of the baseline and 6 m CMR scans are shown in
Table 3. No significant change in arterial pulse pressure
was observed following SAVR (58.8 ± 18.6 vs. 61.4 ±
14.4 mmHg, p = 0.402) or TAVI (63.5 ± 24.0 vs. 69.7 ±
20.3 mmHg, p = 0.203). There was no significant change
in the number of antihypertensive medications used,
neither following SAVR (1.3 ± 0.8 vs. 1.4 ± 0.8, p = 0.503)
or TAVI (1.2 ± 1.0 vs. 1.3 ± 1.0, p = 0.161). Reductions in
aortic valve pressure gradient, valvuloarterial impedance,
LV mass index and end-diastolic volume index were
seen 6 m following both SAVR and TAVI (Table 3).
Aortic stiffness indices
At baseline there was no difference between the groups
in respect to PWV (p = 0.153) or distensibility; neither of
the ascending (p = 0.838) or descending thoracic aortic
(p = 0.306). Change in indices of aortic stiffness are
shown in Fig. 3.
At 6 m, SAVR was associated with a decrease in dis-
tensibility of the ascending aorta (1.95 ± 1.15 vs. 1.57 ±
0.68 × 10−3mmHg−1, p = 0.044) and of the descending
thoracic aorta (3.05 ± 1.12 vs. 2.66 ± 1.00 × 10−3mmHg−1,
p = 0.018). There was a concomitant increase in PWV
observed at 6 m (6.38 ± 4.47 vs. 11.01 ± 5.75 ms−1, p =
0.001) (Table 4). These changes were independent of
whether or not bypass grafting occurred at the time of
valve replacement.
There was no significant change observed in either the
distensibility of the ascending aorta (1.96 ± 1.51 vs. 1.72
± 0.78 × 10−3mmHg−1, p = 0.380) or of the descending
thoracic aorta (2.69 ± 1.79 vs. 2.21 ± 0.79 × 10−3mmHg−1,
p = 0.181) following TAVI. Similarly, TAVI was not
Fig. 2 Patient recruitment pathway
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associated with any significant change in PWV at 6 m
(8.69 ± 6.76 vs. 10.23 ± 7.88 ms−1, p = 0.301) (Fig. 4).
Demographic and procedural factors associated with
change in aortic stiffness
In linear regression analysis, no baseline characteristic
(including age, gender, eGFR, surgical risk score or Zva)
or procedural variable (including surgical times, CABG
and valve type or size) was found to be associated with
any index of increased aortic stiffness after SAVR.
Discussion
Aortic physiology is central to governing the entire car-
diovascular network, serving as a conduit and also regu-
lating coronary perfusion and LV performance. Only a
limited number of studies have evaluated aortic vascular
function following intervention for severe aortic stenosis
[16–21]. The use of M-mode transthoracic echocardiog-
raphy to determine proximal aortic distensibility has
been the exclusive method of investigation; none have
measured local and regional indices simultaneously and
none have sought to compare SAVR directly with TAVI.
Using CMR we have been able to demonstrate that
treatment of severe aortic stenosis with SAVR, compared
to TAVI, is associated with an increase in aortic stiffness
at 6 months independent of baseline characteristics. This
was consistently defined by non-invasive measurement
of both local indices (ascending and descending thoracic
aortic distensibility) and a regional index (aortic arch
pulse wave velocity).
The elastic properties of the aorta relate to its inherent
histological structure, the influence of the autonomic
nervous system and the perfusion of the aortic wall via
vasa vasorum flow [16]. In this regard, the fundamental
difference in the techniques of SAVR and TAVI could
explain our observations.
SAVR involves aortotomy and traumatises aortic wall
integrity with destruction of the vasa vasorum. The re-
moval the periaortic fat (containing the vasa vasorum)
from the ascending aorta in animal studies has been
shown to worsen aortic distensibility acutely due to is-
chemic medial necrosis and altered fibre composition
[22]. In a porcine model, histological analysis of avascu-
lar aorta following surgical manipulation revealed abnor-
mal straightening of the elastin and collagen fibers of
the outer media, resulting in increased aortic stiffness
under a wide range of stresses [23] .
A previous study of 31 patients (mean age 67.2 years)
found a significant reduction in ascending aortic disten-
sibility at 7 days following mechanical AVR (from 2.21
to 1.01), with a recovery towards pre-operative levels at
6 months (1.79) [19]. The authors suggested that the
aetiology was due to “aortic root stunning” implicating
surgical trauma to the aortic wall via cannulation, cool-
ing, clamping, incising and then suturing, all of which
disrupts the aortic wall continuity. None of this occurs
during a conventional TAVI procedure and this may
underscore the findings of our study.
Our study may have missed the early period of aortic root
stunning as we did not examine aortic stiffness acutely and
thus cannot comment on temporal trends post SAVR.
Table 1 Patient characteristics and baseline data
Characteristics SAVR (n = 40) TAVI (n = 32) p value*
Age 72.8 ± 7.0 81 ± 6.3 0.001
Male gender, n (%) 31 (78) 20 (63) 0.151
EuroSCORE II (%) 1.53 ± 1.0 5.66 ± 5.6 0.001
STS Mortality (%) 2.01 ± 0.6 5.68 ± 3.8 0.001
BMI (kgm−2) 27.9 ± 6.3 26.6 ± 2.8 0.274
Systolic BP (mmHg) 131 ± 23 127 ± 28 0.696
Diastolic BP (mmHg) 73 ± 11 65 ± 11 0.003
Resting Heart Rate (bpm) 64 ± 12 65 ± 11 0.713
NYHA class 2.5 ± 0.6 3 ± 1.0 0.002
Previous MI, n (%) 5 (13) 6 (19) 0.560
Previous PCI, n (%) 1 (3) 10 (31) 0.001
Previous CABG, n (%) 0 (0) 12 (38) 0.001
Stroke/TIA, n (%) 7 (18) 4 (13) 0.667
Peripheral vascular
disease, n (%)
1 (3) 6 (19) 0.028
Diabetes Mellitus, n (%) 4 (10) 8 (25) 0.125
Hyperlipidaemia, n (%) 24 (60) 20 (63) 0.977
COPD, n (%) 4 (10) 6 (19) 0.358
Atrial Fibrillation, n (%) 1 (3) 8 (25) 0.006
eGFR (ml/min/1.73 m2) 71.7 ± 13.3 61.4 ± 17.1 0.006
AVA (cm2) 0.90 ± 0.5 0.62 ± 0.2 0.002
Mean PG (mmHg) 43 ± 15.8 51 ± 13.7 0.023
LVEF (%) 52 ± 12 52 ± 13 0.961
ValvuloArterial
Impedance (Zva)
3.88 ± 0.9 4.06 ± 1.6 0.982
Median prosthetic
replacement size (mm)
23 27 0.001
Sinuses of Valsalva
dimension indexed
to BSA (mm/m2)
17.9 ± 2.2 18.1 ± 2.1 0.615
Proximal ascending aortic
dimension indexed
to BSA (mm/m2)
17.4 ± 2.8 16.9 ± 2.8 0.505
Values are mean ± SD or n (%)
Abbreviations: AVA aortic valve area, CABG coronary artery bypass grafting,
eGFR estimated glomerular filtration rate, COPD chronic obstructive
pulmonary disease, MI myocardial infarction, MPG mean pressure gradient by
transthoracic echo, NYHA New York Health Association, PCI percutaneous
coronary intervention, SAVR surgical aortic valve replacement, TAVI
transcatheter aortic valve implantation, Zva valvuloarterial impedance
(systolic arterial pressure +mean echocardiographic transvalvular gradient /
stroke volume index), LVEF left ventricular ejection fraction, BSA body
surface area
*p value for comparison between procedure types
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However our study does suggest that the significant
increase in aortic stiffness persists for at least at
6 months. A decrease in distensibility of the descend-
ing thoracic aorta has not previously been reported.
This finding suggests the surgical insult affects the
aorta more globally, extending beyond the point of
local clamp contact.
Interestingly, we found that bypass time, cross clamp
time, valve size, valve type and concomitant coronary
bypass grafting were not associated with a decline in any
of the parameters of aortic stiffness. This suggests the
deterioration in aortic stiffness seen at the 6 m time
point is insensitive to modifiable surgical technique.
Progressive fragmentation of aortic elastin occurs
throughout adulthood and underlies a reduction in the
Windkessel effect of the aorta, elevating pulse pressures
for a given stroke volume [24]. A recent CMR study
measuring both AD and PWV study in healthy subjects
reported that aortic segments stiffen with age, but that
after the age of 57 years, the ascending aorta is stiffer
than the descending thoracic aorta [25]. We also ob-
served greater distensibility in the descending thoracic
Table 2 Comparison of baseline demographics and aortic stiffness between included and excluded TAVI and SAVR patients
Parameter SAVR included SAVR excluded p value TAVI included TAVI excluded p value
Age (years) 72.8 ± 7.0 70.0 ± 8.4 0.261 81 ± 6.3 80 ± 7.2 0.593
STS score (%) 2.01 ± 0.6 2.06 ± 0.9 0.900 5.68 ± 3.8 5.34 ± 2.8 0.693
EuroSCORE II (%) 1.53 ± 1.0 1.35 ± 0.56 0.116 5.66 ± 5.6 5.18 ± 3.4 0.691
Systolic BP (mmHg) 131 ± 23 127 ± 23 0.557 127 ± 28 132 ± 19 0.524
Previous MI (n (%)) 5 (13) 1 (10) 0.611 6 (19) 4 (15) 0.844
Previous PCI (n (%)) 1 (3) 2 (20) 0.250 10 (31) 8 (31) 0.872
Peripheral Vascular
Disease (n (%))
1 (3) 1 (10) 0.531 6 (19) 6 (23) 0.581
Diabetes Mellitus (n (%)) 4 (10) 4 (40) 0.163 8 (25) 5 (19) 0.721
Hyperlipidaemia, n (%) 24 (60) 8 (80) 0.925 20 (63) 15 (58) 0.998
COPD, n (%) 4 (10) 1 (10) 0.801 6 (19) 5 (19) 0.849
Atrial Fibrillation, n (%) 1 (3) 3 (10) 0.121 8 (25) 5 (19) 0.721
AVA (cm2) 0.90 ± 0.5 0.67 ± 0.2 0.195 0.62 ± 0.2 0.62 ± 0.2 0.941
AAD (×10−3mmHg−1) 1.95 ± 1.15 2.12 ± 1.07 0.648 1.96 ± 1.51 1.55 ± 0.61 0.338
Abbreviations: STS Society of Thoracic Surgeons mortality risk score, AVA aortic valve area, AAD ascending aortic distensibility
Table 3 Preoperative baseline and 6 month follow-up measurements
SAVR TAVI
Baseline 6 months Baseline 6 months
Haemodynamics
Heart Rate (bpm) 64 ± 12 65 ± 11 65 ± 11 66 ± 15
Systolic BP (mmHg) 131 ± 23 133 ± 20 127 ± 28 134 ± 22
Number of Medicationsa 1.3 ± 0.8 1.4 ± 0.8 1.2 ± 1.0 1.3 ± 1.0
Systemic Arterial Complianceb 0.88 ± 0.3 0.74 ± 0.2* 0.81 ± 0.3 0.71 ± 0.2
Aortic Valve
Peak gradient (mmHg)c 59 ± 20 32 ± 18*** 54 ± 14 25 ± 13***
Zva 3.9 ± 0.9 3.5 ± 0.8* 4.1 ± 1.6 3.0 ± 1.1**
Left Ventricle
Mass Index (g/m2) 80 ± 25 65 ± 16*** 82 ± 22 68 ± 18***
EDVI (ml/m2) 95 ± 25 77 ± 14*** 95 ± 25 86 ± 19*
EF (%) 52 ± 12 57 ± 8** 52 ± 13 55 ± 11
Abbreviations: EDVI end diastolic volume indexed to body surface area, EF ejection fraction, Zva valvuloarterial impedance
Paired t test to compare baseline and 6 months: *p < 0.05, **p < 0.01, ***p < 0.001
adefined as any of: ACE inhibitor, angiotensin II receptor antagonist, β blocker, spironolactone, doxazosin, hydralazine, amlodipine, felodipine or bendrofluazide
bDerived as stroke volume index / pulse pressure
cDerived from CMR assessment
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aorta compared to the ascending aorta in both groups at
baseline which reflects this physiological process.
Measures of aortic stiffness, and PWV in particular,
exhibit a strong dependence upon age [26] which must be
factored into the interpretation of our findings. We have
studied two groups with an age difference of approximately
9 years; a reflection of current TAVI implantation criteria.
Although the two groups were statistically comparable for
PWV at baseline, in absolute terms the PWV values are
dissimilar (Fig. 3c); caution is thus required in any clinical
interpretation of change in PWV in these two populations.
However, the ascending AD of the SAVR group and TAVI
group were very similar (1.95 vs. 1.96), yet at 6 months, a
statistically significant decline was seen in the SAVR group,
but not following TAVI.
It is noteworthy the deleterious effect seen following
SAVR was independent of age when entered as a statis-
tical covariate, challenging its potential use in patient
selection pre-operatively. Whilst an ascending AD and
PWV of 1.72 × 10−3mmHg−1 and 10.23 m/s may be ac-
ceptable and expected in patients aged 80 (post-TAVR),
worse values of 1.57 × 10−3mmHg−1 and 11.01 m/s may
not necessarily be acceptable in patients 9 years younger
(post-SAVR), undergoing an intervention for prognostic
reasons who inherently have a lower surgical risk score.
We and others have shown that lowering of blood pres-
sure can improve aortic stiffness [5, 27, 28]. However in this
study, blood pressure and pharmacotherapy were un-
changed pre- and post-procedure, suggesting that this was
unlikely to account for the difference in impact upon aortic
stiffness between TAVI and SAVR. The normal systemic
arterial compliance in both groups indicates that baseline
haemodynamics were governed predominantly by aortic
valve disease without any associated aortic or LV pathology
[4]. Following intervention, SAVR was associated with a
limited decrease in Zva as opposed to TAVI. Given a com-
parable and important reduction in aortic valve gradient
(valvular load), the dampened Zva response to SAVR likely
reflects an increase in arterial load reflecting a mechanical
deterioration in aortic function.
The effect of TAVI upon proximal aortic distensibility
has been assessed once previously in 30 patients (mean age
79.9 years) using echocardiography 7 days post-procedure
[16]. No significant change was observed with an AD of
Fig. 3 Bar charts depicting change in indices of aortic stiffness (3 (a) ascending aortic distensibility, 3 (b) descending aortic distensibility, 3 (c)
pulse wave velocity) seen pre- and post-SAVR and TAVI (mean and standard error bars)
Table 4 Change in mean measurements pre- and post SAVR and TAVI
SAVR TAVI
Pre Post p value* Pre Post p value*
Ascending AD (×10−3mmHg−1) 1.95 ± 1.15 1.57 ± 0.68 0.044 1.96 ± 1.51 1.72 ± 0.78 0.380
Descending AD (×10−3mmHg−1) 3.05 ± 1.12 2.66 ± 1.00 0.018 2.69 ± 1.79 2.21 ± 0.79 0.181
Aortic Arch PWV (m/s) 6.38 ± 4.47 11.01 ± 5.75 0.001 8.69 ± 6.76 10.23 ± 7.88 0.301
Change in AA area** (mm2) 99 ± 54 80 ± 42 0.032 85 ± 32 91 ± 38 0.410
Change in DA area*** (mm2) 87 ± 26 80 ± 27 0.083 73 ± 28 74 ± 25 0.916
Pulse pressure (mmHg) 58 ± 19 61 ± 14 0.322 63 ± 24 70 ± 20 0.150
Length of aortic arch (mm) 139 ± 18 134 ± 20 0.129 126 ± 21 122 ± 16 0.223
*paired samples t-test
**defined as maximal– baseline cross-sectional ascending aortic area
***defined as maximal– baseline cross-sectional descending aortic area
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1.89 pre and 2.05 post TAVI. Our study supports these
findings and additionally demonstrates preservation of local
and regional aortic stiffness at 6 months post-TAVI. Our
study indicates the absence of deterioration in aortic
stiffness out to 6 months post-TAVI may favour its usage
over SAVR in younger patient populations.
The motivation for this study was to investigate whether
TAVI or SAVR is more favourable upon aortic stiffness
and thus potentially prognosis. It might be expected that
our findings would translate into an increased incidence
of adverse cardiovascular events in the surgical popula-
tion. From a meta-analysis of 17 longitudinal studies
comprising 15,877 subjects, an increase in aortic PWV by
1 m/s corresponded to an age-, sex-, and risk factor-
adjusted risk increase of 15 % in all-cause mortality [29].
A dramatic increase in PWV was seen following SAVR in
our study although our follow-up data of the surgical
group extends to an average of 2.8 years with 95 % (n = 38)
of subjects surviving, such that the numbers are insufficient
to make any direct inference.
In the US CoreValve High Risk Study, a higher survival
rate at 1 year in patients undergoing TAVI compared
directly with SAVR was likely due to more rapid recov-
ery coupled with relatively lower rates of stroke [2]. Our
findings are noteworthy in this respect as aortic stiffness
may be a contributory factor to this observation. Indeed,
in a study of 310 patients aged 50 years or more, lower
aortic distensibility was shown to be an independent
predictor of all-cause mortality in patients presenting
with first-ever acute ischemic stroke [30]. Larger studies
with longer follow-up post AVR are required to deter-
mine the precise predictive power of aortic stiffness with
respect to mortality and morbidity in this setting.
Study limitations
The main limitation is the attrition of patients who were
unable to complete the CMR protocol at 6 months. This
was predominantly in the TAVI population who are a very
challenging group to study due to age, frailty and comor-
bidity. Mortality and pacemaker rates were high, but con-
sistent with large international registries. A small number
of TAVI patients declined follow up because of deteriorat-
ing health and transfer into long-term nursing care. This
is one of the largest studies of its kind and patients not
studied at 6 m were not statistically different in demo-
graphics to those that were. Nonetheless, the potential for
bias cannot be excluded as the sickest patients who with-
drew may have had higher post-procedural arterial stiff-
ness and worst outcomes. Furthermore, our final analysed
patient groups were relatively small, giving limited
power to report ‘no difference’ in baseline variables
such as PWV, thus raising the possibility of Type 1
and Type 2 errors, and transfer bias influencing our
final group comparisons. It is possible that our TAVI
population, with an average age of 80 years, may have
reached near maximal aortic stiffness. Thus TAVI it-
self may be deleterious or even beneficial to aortic
stiffness, but our particular population we have not
been able to elucidate this.
The difference in baseline demographics between
the groups was unavoidable due to current TAVI
implantation criteria. However, our study remains un-
precedented, and can be considered a real life reflec-
tion, at least of UK national practice [31]. Finally, this
study has not assessed patients undergoing isolated
on-pump coronary bypass surgery or direct aortic
TAVI.
Fig. 4 Changes in PWV between baseline and 6 months following TAVI and SAVR. (red lines indicate an increase, blue lines represent a decline)
Musa et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:37 Page 8 of 10
Conclusion
In this two centre comparative study using CMR-derived
measurements, treatment of symptomatic severe aortic
stenosis by SAVR but not TAVI was associated with an
increase in aortic stiffness from baseline to 6 m. Given
aortic stiffness is a marker of adverse cardiovascular
events, future work should focus on the potential prognos-
tic benefit of TAVI over SAVR, particularly in younger age-
matched populations, as TAVI implantation criteria evolve.
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